Biohaven LTD 8-K filings

Biohaven announced its second quarter 2024 financial results, highlighting advancements in its drug pipeline, including its MoDE platform and multiple clinical trials.

Biohaven Ltd. has filed a prospectus supplement for the resale of 211,418 common shares by selling shareholders, originally issued as part of a merger agreement.

Biohaven announced its first quarter 2024 financial results, highlighted by a public offering raising $247.8 million and advancements in its clinical pipeline, including its novel MoDE technology.

Biohaven Ltd. held its 2024 annual shareholder meeting, electing three directors, ratifying the appointment of Ernst & Young LLP as independent auditors, and approving an annual frequency for executive compensation advisory votes.

Biohaven Ltd. successfully completed a public offering of 6,451,220 common shares, including the full exercise of the underwriters' option, raising approximately $264.5 million in gross proceeds.

Biohaven's MoDE technology, a novel approach to targeted extracellular protein degradation, shows promising early results in a Phase 1 study for BHV-1300, demonstrating rapid and selective IgG lowering.

Biohaven Ltd. has filed a prospectus supplement for the resale of 45,883 common shares by selling shareholders, related to previous transactions.

Biohaven Ltd. announced its fourth quarter and full year 2023 financial results, highlighting progress across its clinical programs and upcoming milestones.